
The positive recommendation of Tresiba signals a war for the global diabetes market between the existing market leader Lantus and the new contender Tresiba from Novo Nordisk, and Chief Science Officer in Novo, Mads Krogsgaard, tells Medwatch that the definite aim is to surpass Sanofi’s drug Lantus, which accounts for 70 % of the global market for long-acting insulin at present.
“This is important, because Novo Nordisk has been very powerful on the insulin market, historically speaking. But we also have to admit that, as far as a long-acting insulin goes, our competitor Sanofi has done better with their product Lantus.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app